<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Tocilizumab" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Tocilizumab</book-part-id>
      <title-group>
        <title>Tocilizumab</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>18</day>
          <month>4</month>
          <year>2020</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Tobramycin" document-type="chapter">Tobramycin</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Tofacitinib" document-type="chapter">Tofacitinib</related-object>
    </book-part-meta>
    <body>
      <sec id="Tocilizumab.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Tocilizumab.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Tocilizumab is a humanized monoclonal antibody to the interleukin-6 (IL-6) receptor which is used in the therapy of rheumatoid arthritis and other autoinflammatory conditions. Tocilizumab commonly causes mild serum aminotransferase elevations which are usually short lived and asymptomatic, but has also been linked to rare instances of clinically apparent liver injury with jaundice and occasional reactivation of hepatitis B.</p>
        </sec>
        <sec id="Tocilizumab.Background">
          <title>Background</title>
          <p>Tocilizumab (toe&#x0201d; si liz&#x02019; ue mab) is humanized IgG1 monoclonal antibody to the IL-6 receptor that is used largely as therapy of refractory rheumatoid arthritis and other inflammatory arthritides. Tocilizumab blocks the action of IL-6, which is a key proinflammatory cytokine that mediates a wide spectrum of biologic activities including activation of T cells, differentiation of B cells, induction of acute phase reactants, proliferation of fibroblasts, and damage to cartilage and joints. IL-6 levels are elevated in patients with active rheumatoid arthritis. In controlled trials and open label studies, tocilizumab therapy led to improvements in symptoms and laboratory abnormalities associated with several forms of inflammatory arthritis. Tocilizumab was approved for use in the United States in 2010 and current indications include rheumatoid arthritis, giant cell arteritis and both the polyarticular and systemic forms of juvenile idiopathic arthritis (formerly juvenile rheumatoid arthritis). Tocilizumab is considered a disease modifying antirheumatic drug (DMARD) and improves signs and symptoms of disease and decreases cartilage and tissue destruction. More recently, tocilizumab has also been approved as therapy of the cytokine release syndrome in children. Tocilizumab is typically given by intravenous infusion every 4 weeks, in doses of 4-12 mg/kg depending upon indication and body weight. For intravenous use, tocilizumab is available in single dose vials of 80, 200 and 400 mg (20 mg/mL) under the brand name Actemra. Subcutaneous forms of tocilizumab are also available that can be substituted for the intravenous dosing as single use vials of 162 mg in 0.9 mL. The most frequent side effects are upper respiratory symptoms, headache, infusion reactions and hypertension. Uncommon but potentially severe adverse effects include severe infections, reactivation of tuberculosis and viral infections, gastrointestinal perforation, hepatotoxicity and hypersensitivity reactions including anaphylaxis.</p>
        </sec>
        <sec id="Tocilizumab.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>In registration trials, serum aminotransferase elevations occurred in a high proportion (10% to 50%) of patients receiving tocilizumab. ALT elevations often rose to 1 to 3 times the upper limit of normal (ULN) 2 weeks after each infusion, but decreased towards baseline by the time of the next 4-weekly administration and were usually normal within 8 weeks of stopping the infusions. In some instances (~1% to 2%), levels rose above 5 times the ULN which triggered discontinuation or temporary suspension of treatment. Interestingly, the ALT elevations were somewhat dose related and tended to recur, but did not worsen with repeated exposures. In preapproval registration trials, there were no reports of clinically apparent liver injury with jaundice, and most ALT elevations were without symptoms and with minimal or no elevations in serum bilirubin or alkaline phosphatase levels. Since its licensure and availability, however, tocilizumab therapy has been linked to several instances of clinically apparent liver injury with jaundice. The injury arose after several months of therapy and was predominantly hepatocellular with no immunoallergic or autoimmune features. While the liver injury was severe, it was usually self-limited with complete recovery in 2 to 3 months. In at least one instance, however, the affected patient died with liver failure and hepatic atrophy that seemed to be initiated by tocilizumab therapy.</p>
          <p>Tocilizumab is an immunosuppressive agent, but has not been implicated in causing reactivation of viral infections such as cytomegalovirus and hepatitis B. Most cases of reactivation have occurred in persons with preexisting HBsAg and who did not receive prophylaxis. In patients with anti-HBc without HBsAg in serum, suggesting recovery from previous hepatitis B, tocilizumab rarely causes reactivation and most cases have been mild and subclinical. In several cases reports, tocilizumab has been used safety and without worsening of disease in patients with concurrent chronic hepatitis C, but there has been at least one case report of mild and transient worsening of hepatitis C with its use.</p>
          <p>Likelihood score: C (probable rare cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Tocilizumab.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>Tocilizumab is a monoclonal antibody and has minimal hepatic metabolism. The mechanism by which it causes liver injury is unknown, but may be the result of its effects on the immune system or on the IL-6 pathway which is important in liver regeneration.</p>
        </sec>
        <sec id="Tocilizumab.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>The mild liver injury caused by tocilizumab is generally short lived and resolves within 2 to 6 weeks. The majority of patients can continue the 4 weekly infusions, although dose reduction may be warranted. The more severe, clinically apparent liver injury caused by tocilizumab should trigger its permanent discontinuation. Current recommendations are the patients should be monitored with routine liver tests before starting tocilizumab, every 4 to 8 weeks for the first 6 months and every 3 months thereafter. The effects of reexposure to tocilizumab after clinically apparent liver injury have not been reported, but rechallenge should probably be avoided. On the other hand, there is no reason to suspect that there may be cross sensitivity to hepatic injury between tocilizumab and other immune modulating biologic agents or anti-IL1 blockers such as anakinra, canakinumab and rilonacept.</p>
          <p>Drug Class: <related-object link-type="booklink" source-id="livertox" document-id="AntirheumaticAgents" document-type="chapter">Antirheumatic Agents</related-object></p>
          <p>Other Drugs in the Subclass, <related-object link-type="booklink" source-id="livertox" document-id="InterleukinRcptAntag" document-type="chapter">Interleukin Receptor Antagonists</related-object>: <related-object link-type="booklink" source-id="livertox" document-id="Anakinra" document-type="chapter">Anakinra</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Canakinumab" document-type="chapter">Canakinumab</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Rilonacept" document-type="chapter">Rilonacept</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Sarilumab" document-type="chapter">Sarilumab</related-object></p>
        </sec>
      </sec>
      <sec id="Tocilizumab.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
          <bold>REPRESENTATIVE TRADE NAMES</bold>
        </p>
        <p>Tocilizumab &#x02013; Actemra&#x000ae;</p>
        <p>
          <bold>DRUG CLASS</bold>
        </p>
        <p>Antirheumatic Agents</p>
        <p>
          <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=tocilizumab">COMPLETE LABELING</ext-link>
        </p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Tocilizumab.CHEMICAL_FORMULA_AND_STRUCTU">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Tocilizumab.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Tocilizumab.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Tocilizumab.Tc_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NO.</th>
                <th id="hd_h_Tocilizumab.Tc_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Tocilizumab.Tc_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Tocilizumab.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Tocilizumab</td>
                <td headers="hd_h_Tocilizumab.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://135345962">375823-41-9</ext-link>
                </td>
                <td headers="hd_h_Tocilizumab.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">Monoclonal Antibody</td>
                <td headers="hd_h_Tocilizumab.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">Not Available</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Tocilizumab.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 18 April 2020</p>
        <p>Abbreviations: ULN, upper limit of normal.</p>
        <ref-list id="Tocilizumab.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Tocilizumab.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Drugs used to treat rheumatic and musculospastic disease. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 517-53.<annotation><p><italic toggle="yes">(Expert review of hepatotoxicity published in 1999 before the availability of tocilizumab and other monoclonal antibodies and anticytokines).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Tocilizumab.REF.krensky.2018">
            <mixed-citation publication-type="book">Krensky AM, Azzi JR, Hafler DA. Immunosuppressants and tolerogens. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 637-53.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Tocilizumab.REF3">
            <mixed-citation publication-type="web">
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125276s000MedR.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125276s000MedR.pdf</ext-link>
              <annotation>
                <p>
                  <italic toggle="yes">(FDA website with review of evidence for efficacy and safety of tocilizumab mentions that tocilizumab is associated with liver enzyme abnormalities but not with severe clinical liver injury, ALT elevations occurring in 39-52% of treated patients compared to 17% of placebo controls with elevations above 5 times ULN in less than 1% and no episodes of clinically apparent liver injury convincingly linked to tocilizumab).</italic>
                </p>
              </annotation>
            </mixed-citation>
          </ref>
          <ref id="Tocilizumab.REF.bywaters.1971.121">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Bywaters</surname>
                  <given-names>EG</given-names>
                </name>
              </person-group>
              <article-title>Still's disease in the adult.</article-title>
              <source>Ann Rheum Dis</source>
              <year>1971</year>
              <volume>30</volume>
              <fpage>121</fpage>
              <lpage>33</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Clinical description of 14 patients with adult Still disease seen at a single referral center in the UK over a 25 year period; all woman, ages 17-35 years, presenting with urticarial, macular rash, high fevers, fatigue and arthritis, high ESR but no rheumatoid factor, the majority ultimately recovering completely without residual arthritis or problems).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">5315135</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.andr_s.2003.192">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Andr&#x000e8;s</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Kurtz</surname>
                  <given-names>JE</given-names>
                </name>
                <name name-style="western">
                  <surname>Perrin</surname>
                  <given-names>AE</given-names>
                </name>
                <name name-style="western">
                  <surname>Pflumio</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Ruellan</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Goichot</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Dufour</surname>
                  <given-names>P</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Retrospective monocentric study of 17 patients with adult Still's disease, with special focus on liver abnormalities.</article-title>
              <source>Hepatogastroenterology</source>
              <year>2003</year>
              <volume>50</volume>
              <fpage>192</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 17 patients with adult onset Still disease seen at a single French referral center, mean age was 27 years and 76% had moderate liver dysfunction with hepatomegaly in 47% [bilirubin 0.6-1.3 mg/dL, ALT 32-252 U/L], all having "complete recovery").</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">12630021</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.maini.2006.2817">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Maini</surname>
                  <given-names>RN</given-names>
                </name>
                <name name-style="western">
                  <surname>Taylor</surname>
                  <given-names>PC</given-names>
                </name>
                <name name-style="western">
                  <surname>Szechinski</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Pavelka</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Br&#x000f6;ll</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Balint</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Emery</surname>
                  <given-names>P</given-names>
                </name>
                <etal/>
                <collab>CHARISMA Study Group</collab>
              </person-group>
              <article-title>Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.</article-title>
              <source>Arthritis Rheum</source>
              <year>2006</year>
              <volume>54</volume>
              <fpage>2817</fpage>
              <lpage>29</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(359 patients with active rheumatoid arthritis were randomized to different doses of tocilizumab or placebo with or without methotrexate; mild increases in ALT [by 45-88% from baseline] were common with the combination and with higher doses, but were transient and not associated with symptoms or jaundice).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">16947782</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.plushner.2008.1660">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Plushner</surname>
                  <given-names>SL</given-names>
                </name>
              </person-group>
              <article-title>Tocilizumab: an interleukin-6 receptor inhibitor for the treatment of rheumatoid arthritis.</article-title>
              <source>Ann Pharmacother</source>
              <year>2008</year>
              <volume>42</volume>
              <fpage>1660</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of pharmacology, clinically efficacy and safety of tocilizumab mentions that dose dependent liver enzyme elevations were frequent during therapy, but that "most levels returned to near normal at follow-up").</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18957621</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.feist.2009.128">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Feist</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Burmester</surname>
                  <given-names>GR</given-names>
                </name>
              </person-group>
              <article-title>Is tocilizumab in combination with traditional DMARDs safe and effective for patients with active RA?</article-title>
              <source>Nat Clin Pract Rheumatol</source>
              <year>2009</year>
              <volume>5</volume>
              <fpage>128</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Editorial mentions that liver enzyme elevations occur in 45% of patients treated with tocilizumab, but were transient and asymptomatic).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">19252516</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.nishimoto.2009.1580">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Nishimoto</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Miyasaka</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Yamamoto</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Kawai</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Takeuchi</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Azuma</surname>
                  <given-names>J</given-names>
                </name>
              </person-group>
              <article-title>Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.</article-title>
              <source>Ann Rheum Dis</source>
              <year>2009</year>
              <volume>68</volume>
              <fpage>1580</fpage>
              <lpage>4</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 143 patients with rheumatoid arthritis who were continued in an extension trial of tocilizumab for up to 5 years, serum ALT elevations [&#x0003e;2.5 times ULN] occurred in 10%, but most elevations were transient and there were no serious liver related adverse events).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">19019888</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.furst.2010.327">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Furst</surname>
                  <given-names>DE</given-names>
                </name>
              </person-group>
              <article-title>The risk of infections with biologic therapies for rheumatoid arthritis.</article-title>
              <source>Semin Arthritis Rheum</source>
              <year>2010</year>
              <volume>39</volume>
              <fpage>327</fpage>
              <lpage>46</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of the excess risk of infections during biologic therapy of rheumatoid arthritis mentions that the rate of infections was 2.1% in treated patients vs 0.4% in controls; infections were primarily pneumonia and skin infections, none were fatal and few were opportunistic).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">19117595</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.carroll.2011.533">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Carroll</surname>
                  <given-names>MB</given-names>
                </name>
              </person-group>
              <article-title>The impact of biologic response modifiers on hepatitis B virus infection.</article-title>
              <source>Expert Opin Biol Ther</source>
              <year>2011</year>
              <volume>11</volume>
              <fpage>533</fpage>
              <lpage>44</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of reactivation of hepatitis B by biologic response modifiers; tocilizumab has not been linked to reactivation of HBV, although the experience in treating patients with HBsAg has been limited).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21269234</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.schiff.2011.r141">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Schiff</surname>
                  <given-names>MH</given-names>
                </name>
                <name name-style="western">
                  <surname>Kremer</surname>
                  <given-names>JM</given-names>
                </name>
                <name name-style="western">
                  <surname>Jahreis</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Vernon</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Isaacs</surname>
                  <given-names>JD</given-names>
                </name>
                <name name-style="western">
                  <surname>van Vollenhoven</surname>
                  <given-names>RF</given-names>
                </name>
              </person-group>
              <article-title>Integrated safety in tocilizumab clinical trials.</article-title>
              <source>Arthritis Res Ther</source>
              <year>2011</year>
              <volume>13</volume>
              <fpage>R141</fpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Analysis of safety data from 5 large clinical trials and extension studies of tocilizumab in 8580 patients with rheumatoid arthritis treated for up to 5 years; ALT elevations occurred in 19-33% of patients and were above 3 times ULN in 1.1-3.7%, being more frequent with higher doses; dose reductions for ALT elevations occurred in 9.3% and stopping therapy in 2.3% of patients; however, "no evidence was seen of clinically significant hepatitis or drug-induced liver injury associated with transaminase elevations in patients treated with tocilizumab"; 11 liver biopsies showed either nonalcoholic fatty liver disease or were normal).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21884601</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.koike.2011.2148">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Koike</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Harigai</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Inokuma</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Ishiguro</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Ryu</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Takeuchi</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Takei</surname>
                  <given-names>S</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients.</article-title>
              <source>Ann Rheum Dis</source>
              <year>2011</year>
              <volume>70</volume>
              <fpage>2148</fpage>
              <lpage>51</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Evaluation of adverse event reports during the first 1.5 years of tocilizumab availability in Japan; among 3004 reports from 1641 patients, most common were infections followed by laboratory test abnormalities and "hepatobiliary disorders" [n=269 of which 12 were serious], but no details given).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21852254</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.bannwarth.2011.123">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Bannwarth</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Richez</surname>
                  <given-names>C</given-names>
                </name>
              </person-group>
              <article-title>Clinical safety of tocilizumab in rheumatoid arthritis.</article-title>
              <source>Expert Opin Drug Saf</source>
              <year>2011</year>
              <volume>10</volume>
              <fpage>123</fpage>
              <lpage>31</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of the adverse events reported in clinical trials of tocilizumab in rheumatoid arthritis; among 3689 patients with normal ALT levels before treatment, 10.3% had ALT elevations &#x0003e;3 times ULN and 2.4% above 5 times ULN, but there were no cases of clinical apparent liver injury).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21121872</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.hiura.2011.492">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hiura</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Abe</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Tabaru</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Shimajiri</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Hanami</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Saito</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Tanaka</surname>
                  <given-names>Y</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Case of severe liver damage after the induction of tocilizumab therapy for rheumatoid vasculitis.</article-title>
              <source>Hepatol Res</source>
              <year>2011</year>
              <volume>41</volume>
              <fpage>492</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(71 year old man with refractory rheumatoid arthritis and vasculitis developed mild serum enzyme elevations during 3 months of tocilizumab therapy [bilirubin 1.3 mg/dL, ALT 67 U/L, Alk P 380 U/L, platelets 93,000/&#x003bc;L], later developing ascites, and hepatic failure, autopsy showing hepatic atrophy and little fibrosis).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21435128</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.lee.2011.365">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>JS</given-names>
                </name>
                <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Martin</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Germer</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Kenwright</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Benayed</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Spleiss</surname>
                  <given-names>O</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab.</article-title>
              <source>Pharmacogenet Genomics</source>
              <year>2011</year>
              <volume>21</volume>
              <fpage>365</fpage>
              <lpage>74</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Two of 1187 patients with rheumatoid arthritis who developed a concurrent rise in ALT &#x0003e;3 times ULN and serum bilirubin &#x0003e;2 times ULN during tocilizumab therapy were both found to be homozygous for genetic variants of UGT1A1 associated with indirect hyperbilirubinemia and Gilbert syndrome).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21412181</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.kishida.2011.215">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Kishida</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Okuda</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Onishi</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Takebayashi</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Matoba</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Jouyama</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Yamada</surname>
                  <given-names>A</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis.</article-title>
              <source>Mod Rheumatol</source>
              <year>2011</year>
              <volume>21</volume>
              <fpage>215</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(40 year old man with hepatitis B and adult onset Still disease was treated with tocilizumab while receiving entecavir and did not have a rise in HBV DNA levels or worsening of liver disease during anti-IL6 therapy).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">20931272</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.mahamid.2011.657">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Mahamid</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Paz</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Reuven</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Safadi</surname>
                  <given-names>R</given-names>
                </name>
              </person-group>
              <article-title>Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports.</article-title>
              <source>Int J Gen Med</source>
              <year>2011</year>
              <volume>4</volume>
              <fpage>657</fpage>
              <lpage>60</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(46 year old woman with rheumatoid arthritis who was switched from methotrexate [10 years] to tocilizumab and developed fatigue after a 2nd infusion, a liver biopsy showing steatosis and "focal hemorrhagic necrosis" despite normal serum enzymes and bilirubin; later continuing tocilizumab without change in liver tests).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21941451</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.mahamid.2011.39">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Mahamid</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Mader</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Safadi</surname>
                  <given-names>R</given-names>
                </name>
              </person-group>
              <article-title>Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions.</article-title>
              <source>Clin Pharmacol</source>
              <year>2011</year>
              <volume>3</volume>
              <fpage>39</fpage>
              <lpage>43</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Description of same two patients as in Mahamid [Int J Gen Med 2011]).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">22287855</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.iebba.2012.212381">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Iebba</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Di Sora</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Tarasi</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Leti</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Montella</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Montella</surname>
                  <given-names>F.</given-names>
                </name>
              </person-group>
              <article-title>Case report: safety and efficacy of tocilizumab in a patient with rheumatoid arthritis and chronic hepatitis C.</article-title>
              <source>Case Rep Med</source>
              <year>2012</year>
              <volume>2012</volume>
              <elocation-id>212381</elocation-id>
              <annotation>
                <p>
                  <italic toggle="yes">(71 year old woman with chronic hepatitis C and rheumatoid arthritis refractory to therapy with methotrexate and anti-TNF agents was treated with tocilizumab with excellent response and no change in serum enzyme levels [which remained normal] during 6 months of treatment).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">22431927</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF21">
            <element-citation publication-type="journal">
              <article-title>Drugs for rheumatoid arthritis.</article-title>
              <source>Treat Guidel Med Lett</source>
              <year>2012</year>
              <volume>10</volume>
              <issue>117</issue>
              <fpage>37</fpage>
              <lpage>44</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Concise summary on current therapies of rheumatoid arthritis mentions that side effects of tocilizumab include infusion reactions, hypertension, neutropenia, aminotransferase elevations and dyslipidemia).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">22538522</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.de_benedetti.2012.2385">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>De Benedetti</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Brunner</surname>
                  <given-names>HI</given-names>
                </name>
                <name name-style="western">
                  <surname>Ruperto</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Kenwright</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Wright</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Calvo</surname>
                  <given-names>I</given-names>
                </name>
                <name name-style="western">
                  <surname>Cuttica</surname>
                  <given-names>R</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>PRINTO; PRCSG. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.</article-title>
              <source>N Engl J Med</source>
              <year>2012</year>
              <volume>367</volume>
              <fpage>2385</fpage>
              <lpage>95</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 112 children with systemic juvenile idiopathic arthritis not responding to standard therapy in a 12 week, placebo controlled trial, ALT elevations occurred in 19% of 75 tocilizumab recipients [and were &#x0003e;5 times ULN in 7%], but in none of 37 placebo recipients).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23252525</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.sandborg.2012.2439">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Sandborg</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Mellins</surname>
                  <given-names>ED</given-names>
                </name>
              </person-group>
              <article-title>A new era in the treatment of systemic juvenile idiopathic arthritis.</article-title>
              <source>N Engl J Med</source>
              <year>2012</year>
              <volume>367</volume>
              <fpage>2439</fpage>
              <lpage>40</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Editorial in response to De Benedetti [2012] on IL-6 antagonists as therapy of juvenile idiopathic arthritis; "the therapeutic benefits of these biologic agents will need to be weighed against the apparent risks of infection, neutropenia and liver dysfunction").</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23252530</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.nagashima.2012.2231">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Nagashima</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Maruyama</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Kamata</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Minota</surname>
                  <given-names>S</given-names>
                </name>
              </person-group>
              <article-title>Unchanged serum viral load and liver function during tocilizumab treatment in a patient with rheumatoid arthritis and hepatitis C virus infection.</article-title>
              <source>Rheumatol Int</source>
              <year>2012</year>
              <volume>32</volume>
              <fpage>2231</fpage>
              <lpage>2</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(53 year old Japanese man with rheumatoid arthritis and chronic hepatitis C was treated with tocilizumab for 6 months without worsening of his concurrent hepatitis C or change in ALT or HCV RNA levels).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21785953</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.dragonas.2012.1520">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Dragonas</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Ehrenstein</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Fleck</surname>
                  <given-names>M</given-names>
                </name>
              </person-group>
              <article-title>Tocilizumab treatment in a patient suffering from rheumatoid arthritis and concomitant chronic hepatitis C infection.</article-title>
              <source>Rheumatology (Oxford)</source>
              <year>2012</year>
              <volume>51</volume>
              <fpage>1520</fpage>
              <lpage>1</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(47 year old man with rheumatoid arthritis and chronic hepatitis C tolerated tocilizumab therapy with no change in serum enzymes of HCV RNA levels during a full year of treatment).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">22467085</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.mori.2012.2300">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Mori</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Fujiyama</surname>
                  <given-names>S.</given-names>
                </name>
              </person-group>
              <article-title>Comment on: Tocilizumab treatment in a patient suffering from rheumatoid arthritis and concomitant chronic hepatitis C infection.</article-title>
              <source>Rheumatology (Oxford)</source>
              <year>2012</year>
              <volume>51</volume>
              <fpage>2300</fpage>
              <lpage>2</lpage>
              <lpage>author reply 2302</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Letter in response to Dragonas [2012] describing a 65 year old woman with rheumatoid arthritis and chronic hepatitis C who had a flare of disease [ALT 211 U/L, HCV RNA levels rising slightly, bilirubin not given] after 8 months of tocilizumab therapy, resolving upon stopping).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">22977061</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.akgul.2013.137">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Akgul</surname>
                  <given-names>O</given-names>
                </name>
                <name name-style="western">
                  <surname>Kilic</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Kilic</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Ozgocmen</surname>
                  <given-names>S</given-names>
                </name>
              </person-group>
              <article-title>Efficacy and safety of biologic treatments in familial Mediterranean Fever.</article-title>
              <source>Am J Med Sci</source>
              <year>2013</year>
              <volume>346</volume>
              <fpage>137</fpage>
              <lpage>41</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Systematic review of reports on use of biologic response modifiers in familial Mediterranean fever identified no controlled trials, but 24 single reports and 7 case series describing 59 patients; agents evaluated included TNF antagonists [35], anakinra [29], and canakinumab [4], but not tocilizumab; no discussion of hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23276893</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.gabay.2013.1541">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Gabay</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Emery</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>van Vollenhoven</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Dikranian</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Alten</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Pavelka</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Klearman</surname>
                  <given-names>M</given-names>
                </name>
                <etal/>
                <collab>ADACTA Study Investigators</collab>
              </person-group>
              <article-title>Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.</article-title>
              <source>Lancet</source>
              <year>2013</year>
              <volume>381</volume>
              <issue>9877</issue>
              <fpage>1541</fpage>
              <lpage>50</lpage>
              <comment>Erratum in</comment>
              <pub-id pub-id-type="pmid">23515142</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF29">
            <mixed-citation publication-type="other">Lancet 2013; 382(9908): 1878, and Lancet 2013; 381(9877): 1540, dosage error in article text.<annotation><p><italic toggle="yes">(Controlled trial comparing 24 week courses of 2 monoclonal antibody therapies in 326 patients with rheumatoid arthritis; ALT elevations above 2.5 times ULN occurred in 6% on tocilizumab vs 1.9% on adalimumab, but there were no serious adverse events attributed to liver injury).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Tocilizumab.REF.alfreijat.2013.1340">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Alfreijat</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Habibi</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Bhatia</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Bhatia</surname>
                  <given-names>A</given-names>
                </name>
              </person-group>
              <article-title>Severe hepatitis associated with tocilizumab in a patient with rheumatoid arthritis.</article-title>
              <source>Rheumatology (Oxford)</source>
              <year>2013</year>
              <volume>52</volume>
              <fpage>1340</fpage>
              <lpage>1</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(62 year old man with rheumatoid arthritis developed jaundice 1 week after a 3rd monthly injection of tocilizumab [bilirubin 10.5, ALT 2296, Alk P not given], resolving within 10 weeks on prednisone; accompanied by mild pancreatitis).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23315786</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.drepper.2013.964828">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Drepper</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Rubbia-Brandt</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Spahr</surname>
                  <given-names>L</given-names>
                </name>
              </person-group>
              <article-title>Tocilizumab-induced acute liver injury in adult onset Still's disease.</article-title>
              <source>Case Reports Hepatol</source>
              <year>2013</year>
              <volume>2013</volume>
              <elocation-id>964828</elocation-id>
              <annotation>
                <p>
                  <italic toggle="yes">(18 year old woman with Still disease developed jaundice 6 months after starting tocilizumab [bilirubin 3.6 mg/dL, ALT 2628 U/L, Alk P 110 U/L, INR 1.21], with liver biopsy showing centrilobular necrosis, and resolving within 1 month of stopping).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25374723</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.giannitti.2013.816">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Giannitti</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Fineschi</surname>
                  <given-names>I</given-names>
                </name>
                <name name-style="western">
                  <surname>Frediani</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Fioravanti</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Galeazzi</surname>
                  <given-names>M</given-names>
                </name>
              </person-group>
              <article-title>Efficacy and safety of tocilizumab combined with cyclosporine A in a patient with rheumatoid arthritis and concomitant chronic hepatitis C virus infection.</article-title>
              <source>Clin Exp Rheumatol</source>
              <year>2013</year>
              <volume>31</volume>
              <fpage>816</fpage>
              <annotation>
                <p>
                  <italic toggle="yes">(58 year old man with rheumatoid arthritis and chronic hepatitis C tolerated treatment with tocilizumab, cyclosporine and prednisone for 12 months with no worsening of ALT levels or increase in HCV RNA levels).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24021246</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.genovese.2013.768">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Genovese</surname>
                  <given-names>MC</given-names>
                </name>
                <name name-style="western">
                  <surname>Rubbert-Roth</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Smolen</surname>
                  <given-names>JS</given-names>
                </name>
                <name name-style="western">
                  <surname>Kremer</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Khraishi</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>G&#x000f3;mez-Reino</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Sebba</surname>
                  <given-names>A</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure.</article-title>
              <source>J Rheumatol</source>
              <year>2013</year>
              <volume>40</volume>
              <fpage>768</fpage>
              <lpage>80</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Analysis of long term safety data from 5 controlled trials and open label extension studies of tocilizumab given for an average of 3 years in 4009 patients with rheumatoid arthritis; 3 hepatic serious adverse events occurred, autoimmune hepatitis, steatosis and hepatic ischemia, the last being possibly related as it occurred in a patient with an anaphylactic reaction).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23457383</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.burmester.2014.69">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Burmester</surname>
                  <given-names>GR</given-names>
                </name>
                <name name-style="western">
                  <surname>Rubbert-Roth</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Cantagrel</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Hall</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Leszczynski</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Feldman</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Rangaraj</surname>
                  <given-names>MJ</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study).</article-title>
              <source>Ann Rheum Dis</source>
              <year>2014</year>
              <volume>73</volume>
              <fpage>69</fpage>
              <lpage>74</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Comparison of weekly subcutaneous injections to every 4 weekly intravenous infusions of tocilizumab in 1262 patients with rheumatoid arthritis; the safety profiles were similar except for injection site reactions; some degree of ALT elevation occurred in 52% of patients and were &#x0003e;3 times ULN in 5% and &#x0003e;5 times ULN in 1%).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23904473</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.bauer.2015.e675">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Bauer</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Luxembourger</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Gottenberg</surname>
                  <given-names>JE</given-names>
                </name>
                <name name-style="western">
                  <surname>Fournier</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Abravanel</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Cantagrel</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Chatelus</surname>
                  <given-names>E</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Club Rhumatismes et Inflammation, a section of the French Society of Rheumatology. Outcome of hepatitis E virus infection in patients with inflammatory arthritides treated with immunosuppressants: a French retrospective multicenter study.</article-title>
              <source>Medicine (Baltimore)</source>
              <year>2015</year>
              <volume>94</volume>
              <elocation-id>e675</elocation-id>
              <annotation>
                <p>
                  <italic toggle="yes">(Survey of French physicians treating patients with rheumatic diseases identified 23 patients who developed acute hepatitis E while being treated with immunosuppressive regimens [10 on anti-TNF, 4 rituximab, 2 abatacept, 2 tocilizumab and 16 receiving methotrexate, 4 leflunomide and 1 cyclosporine]; all recovered and cleared HEV RNA, some after reduction in immunosuppression and 5 with ribavirin therapy).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25860212</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.curtis.2015.381">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Curtis</surname>
                  <given-names>JR</given-names>
                </name>
                <name name-style="western">
                  <surname>Perez-Gutthann</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Suissa</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Napalkov</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Singh</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Thompson</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Porter-Brown</surname>
                  <given-names>B</given-names>
                </name>
                <collab>Actemra Pharmacoepidemiology Board</collab>
              </person-group>
              <article-title>Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources.</article-title>
              <source>Semin Arthritis Rheum</source>
              <year>2015</year>
              <volume>44</volume>
              <fpage>381</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Analysis of large postmarketing databases on adverse reactions to tocilizumab combined with data on amounts of drug sold suggested that the rate of serious hepatic adverse events was 0.06 per 100 person-years of exposure [36 events in 31 patients]).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25300699</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.nakamura.2016.470">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Nakamura</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Nagashima</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Nagatani</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Yoshio</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Iwamoto</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Minota</surname>
                  <given-names>S.</given-names>
                </name>
              </person-group>
              <article-title>Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.</article-title>
              <source>Int J Rheum Dis</source>
              <year>2016</year>
              <volume>19</volume>
              <fpage>470</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 244 patients with rheumatoid arthritis started on biologic therapy at a single Japanese referral center, 57 [23%] had serologic evidence of previous HBV infection [anti-HBc without HBsAg in serum], of whom only 3 were identified as having HBV reactivation [including 2 of 18 on tocilizumab and 1 of 50 on anti-TNF agents] but HBV DNA levels were low, not associated with symptoms or liver test abnormalities and only transiently detectable despite continuation of therapy).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24698305</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.komura.2016.1923">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Komura</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Ohta</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Nakai</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Seishima</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Yamato</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Miyazawa</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Kaji</surname>
                  <given-names>K</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Cytomegalovirus reactivation induced acute hepatitis and gastric erosions in a patient with rheumatoid arthritis under treatment with an anti-IL-6 receptor antibody, tocilizumab.</article-title>
              <source>Intern Med</source>
              <year>2016</year>
              <volume>55</volume>
              <fpage>1923</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(54 year old woman with rheumatoid arthritis on prednisone and methotrexate developed fever and CMV viremia with liver test abnormalities 19 days after starting tocilizumab [bilirubin 1.3 mg/dL, ALT 106 U/L, Alk P 495 U/L], improving rapidly with ganciclovir therapy and having normal liver tests 8 weeks later).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">27432105</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.genovese.2017.1751">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Genovese</surname>
                  <given-names>MC</given-names>
                </name>
                <name name-style="western">
                  <surname>Kremer</surname>
                  <given-names>JM</given-names>
                </name>
                <name name-style="western">
                  <surname>van Vollenhoven</surname>
                  <given-names>RF</given-names>
                </name>
                <name name-style="western">
                  <surname>Alten</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Scali</surname>
                  <given-names>JJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Kelman</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Dimonaco</surname>
                  <given-names>S</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Transaminase levels and hepatic events during tocilizumab treatment: pooled analysis of long-term clinical trial safety data in rheumatoid arthritis.</article-title>
              <source>Arthritis Rheumatol</source>
              <year>2017</year>
              <volume>69</volume>
              <fpage>1751</fpage>
              <lpage>61</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 4171 patients with rheumatoid arthritis treated in clinical trials with tocilizumab for an average of 3.9 years, routine monitoring showed at least one ALT abnormality in 71% but most were mild and transient and arose during the first year of therapy, only 3% were above 5 times ULN, 2.5% resulted in drug discontinuation and only 7 subjects had a severe hepatic adverse event [cirrhosis, acute liver failure, ascites, steatosis, ischemic hepatitis and autoimmune hepatitis], none of which were very convincingly linked to tocilizumab).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">28597609</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.anger.2017.1628">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Anger</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Wiegering</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Wagner</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Lock</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Baur</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Haug</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Schmalzing</surname>
                  <given-names>M</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Toxic drug-induced liver failure during therapy of rheumatoid arthritis with tocilizumab subcutaneously: a case report.</article-title>
              <source>Rheumatology (Oxford)</source>
              <year>2017</year>
              <volume>56</volume>
              <fpage>1628</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(51 year old woman with rheumatoid arthritis developed liver enzyme elevations 5 years after starting tocilizumab which continued to worsen despite stopping drug with jaundice arising 3 months later followed by progressive hepatic failure and liver transplantation).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">28575416</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.fromholdtreu.2017.467">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Fromhold-Treu</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Erbersdobler</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Turan</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Neeck</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Lamprecht</surname>
                  <given-names>G.</given-names>
                </name>
              </person-group>
              <comment>[CMV associated acute liver failure in a patient receiving tocilizumab for systemic lupus erythematosus]</comment>
              <source>Z Gastroenterol</source>
              <year>2017</year>
              <volume>55</volume>
              <fpage>467</fpage>
              <lpage>72</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(41 year old woman with systemic lupus treated with prednisone, azathioprine or tocilizumab developed CMV hepatitis [bilirubin 14.8 mg/dL, ALT 430 U/L, Alk P 171 U/L, INR 2.1], resolving with increase in corticosteroid dose and valganciclovir).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">28499323</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.chen.2017.859">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>LF</given-names>
                </name>
                <name name-style="western">
                  <surname>Mo</surname>
                  <given-names>YQ</given-names>
                </name>
                <name name-style="western">
                  <surname>Jing</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Ma</surname>
                  <given-names>JD</given-names>
                </name>
                <name name-style="western">
                  <surname>Zheng</surname>
                  <given-names>DH</given-names>
                </name>
                <name name-style="western">
                  <surname>Dai</surname>
                  <given-names>L</given-names>
                </name>
              </person-group>
              <article-title>Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.</article-title>
              <source>Int J Rheum Dis</source>
              <year>2017</year>
              <volume>20</volume>
              <fpage>859</fpage>
              <lpage>69</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 7 patients with rheumatoid arthritis and HBsAg in serum treated with 4 infusions of tocilizumab 1 month apart, 3 [of 5 without prophylaxis] developed reactivation of hepatitis B, which resolved rapidly and without ALT elevations with prompt antiviral therapy; of 41 patients with resolved HBV infection [anti-HBc without HBsAg], none developed reactivation).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">28160426</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.ikeuchi.2018.6873276">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Ikeuchi</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Koinuma</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Nakasatomi</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Sakairi</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Kaneko</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Maeshima</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Yamazaki</surname>
                  <given-names>Y</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Hepatitis E during tocilizumab therapy in a patient with rheumatoid arthritis: case report and literature review.</article-title>
              <source>Case Rep Rheumatol</source>
              <year>2018</year>
              <volume>2018</volume>
              <elocation-id>6873276</elocation-id>
              <annotation>
                <p>
                  <italic toggle="yes">(63 year old woman with rheumatoid arthritis developed liver test abnormalities 10 months after starting tocilizumab which were found to be due to acute hepatitis E [bilirubin normal, ALT 523 U/L, Alk P 377 U/L, HEV RNA positive, genotype 3], which resolved spontaneously).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">30147981</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.ahn.2018.452">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Ahn</surname>
                  <given-names>SS</given-names>
                </name>
                <name name-style="western">
                  <surname>Jung</surname>
                  <given-names>SM</given-names>
                </name>
                <name name-style="western">
                  <surname>Song</surname>
                  <given-names>JJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Park</surname>
                  <given-names>YB</given-names>
                </name>
                <name name-style="western">
                  <surname>Park</surname>
                  <given-names>JY</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>SW</given-names>
                </name>
              </person-group>
              <article-title>Safety of tocilizumab in rheumatoid arthritis patients with resolved hepatitis B virus infection: data from real-world experience.</article-title>
              <source>Yonsei Med J</source>
              <year>2018</year>
              <volume>59</volume>
              <fpage>452</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 15 patients with rheumatoid arthritis who were positive for anti-HBc and were treated with tocilizumab without receiving prophylaxis, none developed reactivation of hepatitis B during an average of 9 months of treatment).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">29611409</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.ben_said.2018.1048">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Ben Said</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Gerfaud-Valentin</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Seve</surname>
                  <given-names>P.</given-names>
                </name>
              </person-group>
              <article-title>Fatal DRESS syndrome under tocilizumab treatment for seronegative polyarthritis.</article-title>
              <source>J Allergy Clin Immunol Pract</source>
              <year>2018</year>
              <volume>6</volume>
              <fpage>1048</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(69 year old woman with seronegative arthritis developed rash, fever and eosinophilia 3 months after starting tocilizumab with liver abnormalities and progressive jaundice [bilirubin 32.8, ALT 511 U/L] and complications of pancytopenia, hemophagocytic syndrome, CMV viremia and death from progressive hepatic failure 4 months after onset).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">29126664</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.papalopoulos.2018.102">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Papalopoulos</surname>
                  <given-names>I</given-names>
                </name>
                <name name-style="western">
                  <surname>Fanouriakis</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Kougkas</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Flouri</surname>
                  <given-names>I</given-names>
                </name>
                <name name-style="western">
                  <surname>Sourvinos</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Bertsias</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Repa</surname>
                  <given-names>A</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study.</article-title>
              <source>Clin Exp Rheumatol</source>
              <year>2018</year>
              <volume>36</volume>
              <fpage>102</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 212 patients with rheumatic disease and anti-HBc without HBsAg in serum who were treated with biologic agents without HBV prophylaxis for an average of 24 months, 1 of 39 on abatacept, 1 of 32 on rituximab, but none of 30 on tocilizumab or 111 on anti-TNF agents developed hepatitis B reactivation).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">28850029</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.sonneveld.2019.e00243">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Sonneveld</surname>
                  <given-names>MJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Murad</surname>
                  <given-names>SD</given-names>
                </name>
                <name name-style="western">
                  <surname>van der Eijk</surname>
                  <given-names>AA</given-names>
                </name>
                <name name-style="western">
                  <surname>de Man</surname>
                  <given-names>RA</given-names>
                </name>
              </person-group>
              <article-title>Fulminant liver failure due to hepatitis B reactivation during treatment with tocilizumab.</article-title>
              <source>ACG Case Rep J</source>
              <year>2019</year>
              <volume>6</volume>
              <elocation-id>e00243</elocation-id>
              <annotation>
                <p>
                  <italic toggle="yes">(59 year old Chinese woman with rheumatoid arthritis and HBsAg in serum [HBV DNA 88 IU/mL] on prednisone, leflunomide and hydroxychloroquine developed clinically apparent reactivation of hepatitis B shortly after starting tocilizumab [bilirubin rising to 25.3 mg/dL, peak ALT 2125 U/L, HBV DNA 3.6 billion IU/mL] and despite starting entecavir developed progressive liver failure and underwent successful liver transplantation).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">32042838</pub-id>
            </element-citation>
          </ref>
          <ref id="Tocilizumab.REF.brazdilova.2019.s157">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Brazdilova</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Koller</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Killinger</surname>
                  <given-names>Z</given-names>
                </name>
                <name name-style="western">
                  <surname>Payer</surname>
                  <given-names>J</given-names>
                </name>
              </person-group>
              <article-title>Prevalence and risk factors for drug-induced liver injury among patients with rheumatic diseases treated with biological therapy: a single-center experience.</article-title>
              <source>Physiol Res</source>
              <year>2019</year>
              <volume>68</volume>
              <supplement>Suppl 2</supplement>
              <fpage>S157</fpage>
              <lpage>S163</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 199 patients with rheumatic diseases treated with biologic agents, 51 [26%] had ALT elevations during therapy including 24 of 96 [25%] on tocilizumab, but elevations were mostly mild and transient, only 3 patients had values above 3 times ULN none of whom were receiving tocilizumab).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">31842579</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Tocilizumab.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <label>1</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=Tocilizumab+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Tocilizumab: from PubMed.gov</ext-link>
            </p>
          </list-item>
          <list-item>
            <label>2</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Tocilizumab">Trials on Tocilizumab: from ClinicalTrials.gov</ext-link>
            </p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
